BIO VentureForum 2001 to Showcase 89 Leading Life Sciences Investment Opportunities
"BIO VentureForum's list of presenting companies is very impressive," said Michael Lytton, general partner at Oxford BioScience Partners and a member of the event's advisory board. "This is the only comprehensive conference that provides venture capitalists with direct access to the best entrepreneurial investment opportunities in life sciences."
Selected from across the United States, Europe and Asia, the presenting companies deliver cutting-edge therapies and technologies, including genomics, proteomics, chemistry and bioinformatics. California, Maryland and North Carolina are home to more than half of BIO VentureForum's participating businesses.
A complete list of presenting companies follows, and more information can be found at www.bioventureforum.net.
"Fueled by dynamic breakthroughs such as the mapping of the human genome, the biotechnology industry has established itself as a fast-growing market sector and has created remarkable opportunities for new drug discoveries and technologies," said BIO President Carl B. Feldbaum. "BIO VentureForum 2001 is an excellent platform for entrepreneurs to showcase promising new treatments to sophisticated investors and advance the product pipeline."
Scott Morrison, Ernst & Young's national director of life sciences, will address BIO VentureForum 2001 on Thursday, October 4, regarding "Focus on Fundamentals: The Biotechnology Report, Ernst & Young's 15th Annual Review."
Attendees will also be able to take advantage of the Technology Council of Maryland's BioScience Forum, co-located at the same venue. The forum will showcase Maryland universities and Maryland-based federal laboratories developing technologies available for commercialization through partnerships with established companies. A series of BioScience panel discussions will cover Bioinformatics/Computational Biology, Biocatalysis/Enzyme Research, Therapeutics, Agriculture/Environmental Applications, Medical Devices, and Diagnostics.
BIO VentureForum 2001 and Maryland BioScience Forum sponsors include Ernst & Young, LLP; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; FireRed.com; Friedman, Billings, Ramsey Group, Inc.; GATX Ventures, Inc.; Heller Ehrman White & McAuliffe LLP; Hogan & Hartson LLP; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC; Nomura International Plc; Reed Smith; Pacific Growth Equities, Inc.; Ropes & Gray; ShawPittman LLP; Silicon Valley Bank; Sun Microsystems; and UBS Warburg.
BIO VentureForum 2001 advisory board members include Academy Funds, Advent International Corporation, Alta Partners, Atlas Venture, Birchmere Ventures II LP, Burill & Company, Delphi Ventures, Dingman Center for Entrepreneurship, Domain Associates, Emerging Technology Partners, Intersouth Partners, InterWest Partners, Johnson & Johnson Development Corporation, Maryland Health Care Product Development Corporation, Mason Wells, MPM Capital Advisors LLC, National Capital Companies, Neuroventures Capital, NextGen Capital, Oxford BioScience Partners, Perseus-Soros Biopharmaceutical Fund, ProQuest Investments, Sofinnova Ventures Inc., S.R. One Ltd., Tenex Medical Investors, The Kaufmann Fund Inc., TVM Techno Venture Management, and Venrock Associates.
For more information on BIO VentureForum 2001, please visit the Web site at www.bioventureforum.net.
About BIO
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit www.bio.org .
BIO VentureForum 2001 Presenting Companies
20/20 Genesystems, Inc.
Achillion Pharmaceutics, Inc.
Addiction Therapies, Inc.
Advancis Pharmaceutical Corporation
Agensys, Inc.
Ancile Pharmaceuticals, Inc.
AngioGenex Inc.
AnVil Informatics, Inc.
Aptus Genomics, Inc.
Archemix Corporation
Artecel Sciences, Inc.
Athenix Solutions, Inc.
Automated Cell, Inc.
Auxilium A2, Inc.
Avantium Technologies B.V.
Big Bear Bio, Inc.
BioMat Sciences, Inc.
BioMicro Systems, Inc.
bioMosaic Systems, Inc.
Bionaut Pharmaceuticals, Inc.
BSI Proteomics Corporation
Cardio Vascular Genetic Engineering, Inc.
Clairus Technologies, Inc.
Claragen, Inc.
Cogent Neurosciences, Inc.
Copharos, Inc.
Corgentech Inc.
CropTech Corporation
CTIS, Inc.
Cytran, Inc.
Demegen Inc.
Diabetogen Biosciences Inc.
Dilon Technologies Inc.
Endeavor Pharmaceuticals, Inc.
EnVivo Pharmaceuticals, Inc.
FASgen, Inc.
First Genetic Trust, Inc.
Fluidigm Corporation
Functional Genetics Inc.
Gala Design, Inc.
Galileo Laboratories, Inc.
Gemin X Biotechnologies Inc.
Geneformatics Inc.
Genetix Pharmaceuticals, Inc.
Genteric, Inc.
Hemodyne, Inc.
ImPres Medical, Inc.
Ingenium Pharmaceuticals AG
Inhibitex Inc.
Intradigm Corporation
Iomai Corporation
Juvenir Biosciences Inc.
Libraria, Inc.
LifeTime Pharmaceuticals, Inc.
Locus Discovery, Inc.
Macrogenics, Inc.
Memory Pharmaceuticals, Inc.
Message Pharmaceuticals, Inc.
Metabolex, Inc.
MetriGenix, Inc.
MithraGen, Inc.
Mojave Therapeutics Inc.
NeuroMed Technologies Inc.
Neuronyx Inc.
Norak Biosciences Inc.
Novasite Pharmaceuticals
Odyssey Pharmaceuticals
Ontogen Corporation
Picoliter, Inc.
Plexxikon, Inc.
Pluvita Corporation
Psychiatric Genomics, Inc.
RenalTech International
Rheogene Inc.
Scimagix, Inc.
Sierra Sciences, Inc.
SLIL Biomedical Corp.
SomaLogic, Inc.
Spectral Genomics, Inc.
StemCo Biomedical, Inc.
Structural Bioinformatics, Inc.
SurfaceLogix, Inc.
Targacept, Inc.
TheraMed, Inc.
Valley Forge Pharmaceuticals, Inc.
Viral Genomix Inc.
Viron Therapeutics Inc.
Vizx Labs, LLC
YM Biosciences Inc.
# # #
For comments, or to subscribe/unsubscribe, please contact Carrie Housman at chousman@bio.org or call (202) 962-9200. Thank you.